ViewRay (VRAYQ) Stock Price, News & Analysis

Company Overview

ViewRay, Inc. was a medical technology company that developed and commercialized MRI-guided radiation therapy systems for cancer treatment. Its principal product, the MRIdian system, combined magnetic resonance imaging with external-beam radiation therapy, allowing clinicians to visualize tumors and nearby organs during treatment and adjust radiation delivery as anatomy changed.

The MRIdian platform was designed to support stereotactic body radiation therapy and other highly targeted procedures. By integrating real-time imaging, treatment planning, and radiation delivery, the system aimed to help physicians treat tumors more precisely while limiting exposure to surrounding healthy tissue. ViewRay marketed its technology to hospitals and cancer centers in the United States and internationally.

ViewRay was formerly listed on the Nasdaq under the symbol VRAY. The company filed for Chapter 11 bankruptcy protection in 2023 and subsequently ceased operating as an independent public company. Its business and technology have since been subject to bankruptcy-related asset transactions. Because ViewRay is no longer an active publicly traded operating company, current information about its leadership and ongoing commercial activities is limited.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,150 shs
• Average Volume: 19,400 shs
• Market Capitalization: $16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:VRAYQ
• CIK: 1597313
• Web: www.viewraysystems.com
• Phone: 440-703-3210
• Fax: 800-417-3459
• Employees: 295
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $102.21 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 164,740,000
• Free Float: 178,817,000
• Market Cap: $16 thousand
• Optionable: No Data
• Beta: 0.77